Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arazlo for Postinflammatory Erythema and Hyperpigmentation in Acne
NCT05704114Phase 4Completed
- Start
- Feb 2021
- Primary completion
- Feb 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 4 trial of tazarotene in Postinflammatory erythema (PIE), Post-inflammatory hyperpigmentation (PIH). Started Feb 2021; status: completed.
02
Drugs
tazarotene
03
Conditions
Postinflammatory erythema (PIE)Post-inflammatory hyperpigmentation (PIH)
Beyond the preview
Go deeper on NCT05704114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05704114.